The AACT toxicology question of the day for today: Dimethyl fumarate has recently been approved for use in the treatment of relapsing forms of multiple sclerosis. The mechanism of action for this drug is not known with certainty however its primary clinical effects may be due to activation of an important antioxidant response pathway. What are the most common adverse effects associated with dimethyl fumarate? Scroll down for the answer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . The most common adverse effects associated with dimethyl fumarate are flushing, abdominal pain, nausea and diarrhea. The cited reference notes that potentially serious lymphopenia can occur and that mean lymphocyte counts can decrease by approximately 30% during the first year of treatment with this drug. (The Medical Letter June 10, 2013, 55(1418): 45-47)
Posted on: Mon, 17 Jun 2013 13:00:06 +0000